Conference call interim report
Rhea-AI Summary
Vitrolife AB (publ) has announced a conference call to present its Q3 2024 interim report. The call is scheduled for Thursday, October 24, 2024, at 10:00 AM CET. Participants must register in advance to receive access details. The presentation will be conducted in English.
Key participants from Vitrolife include CEO Bronwyn Brophy O'Connor and CFO Patrik Tolf. The interim report press release will be issued at 8:00 AM CET on the same day, with presentation materials available on the company's website prior to the call.
A recorded version of the conference call will be accessible for seven days following the event. The company emphasizes that personal data will be processed in accordance with their privacy policy.
Positive
- None.
Negative
- None.
Time: Thursday 24 October, 2024 at 10.00 a.m. CET.
To attend the conference call, please use this link to register. After registration, you will be provided with telephone numbers, conference PIN, and personal PIN to access the conference. Your personal data will be processed in accordance with our privacy policy available at: Privacy policy | Vitrolife Group
Vitrolife Group participants:
Bronwyn Brophy O´Connor, CEO
Patrik Tolf, CFO
The press release for the interim report will be released at 8.00 CET on the same day.
Before the conference call, presentation material will be available at the company web page.
A recorded version of the telephone conference will be available for seven days on number
+44 (0) 20 3451 9993 (International), access code 5081758#.
VITROLIFE AB (publ)
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/vitrolife-ab--publ-/r/conference-call-interim-report,c4049512
The following files are available for download:
Conference call interim report |
View original content:https://www.prnewswire.com/news-releases/conference-call-interim-report-302272770.html
SOURCE Vitrolife AB (publ)